Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.Coverage includes:• Novel therapeutic strategies• High-throughput screening• Therapeutic targets• Combinatorial chemistry, parallel synthesis and library design• Drug delivery• ADME/Tox• Advances in key compound classes and therapeutic areas• Genomics and proteomics• Automation and technology• Virtual chemistry• Informatics• Business strategy• Clinical trialsand other aspects of drug discovery.
《今日药物发现》为发现社区提供了知情的和高度最新的评论。该杂志不仅讨论药物研发相关技术的快速科学发展，还讨论在研发计划、结构和执行中发挥越来越重要作用的管理、商业和监管问题。特色包括国际专家评论、重要发展的新闻和分析、关键科学和战略问题的评论，综述特定治疗领域的最新进展和会议报告。内容包括：·新的治疗策略·高通量筛选·治疗靶点·组合化学、平行合成和文库设计·药物递送· ADME/Tox·关键化合物类别和治疗领域的进展·基因组学和蛋白质组学·自动化和技术·虚拟化学·信息学·商业战略·临床试验和药物发现的其他方面。
Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.08.005
Luxturna: FDA documents reveal the value of a costly gene therapy.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.01.019
Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.003
Towards the development of human immune-system-on-a-chip platforms
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.10.003
Drug repurposing: a promising tool to accelerate the drug discovery process.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.06.014
Therapy for glioblastoma: is it working?
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.008
Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.08.009
The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.022
PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.09.001
TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.12.001
Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.023
Recent advances in intraocular sustained-release drug delivery devices.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.031
Hydrogels for sustained delivery of biologics to the back of the eye.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.037
Evolution of commercially available compounds for HTS.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.10.016
Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.12.007
Alternative splicing, RNA-seq and drug discovery.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.030
Gut reaction: impact of systemic diseases on gastrointestinal physiology and drug absorption.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.009
Skin metabolism phase I and phase II enzymes in native and reconstructed human skin: a short review.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.06.002
Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.01.015
3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.09.003
Efficient drug discovery by rational lead hybridization based on crystallographic overlay.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.021
Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.007
Exploring new technologies in biomedical research.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.001
The importance of target binding kinetics for measuring target binding affinity in drug discovery: a case study from a CRF1 receptor antagonist program.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.09.011
Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.06.001
Better prediction of the local concentration-effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.016
Advances in differentiation therapy for osteosarcoma.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.08.010
Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.11.002
The gap between the need for novel retinal drug delivery methods, technologies in R&D phase, and approved ocular drug delivery technologies.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.018
Unbiased data analytic strategies to improve biomarker discovery in precision medicine.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.018
Emerging targets of inflammation and tear secretion in dry eye disease.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.02.006
Mini-gut: a promising model for drug development.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.06.006
Recent developments in liposomal drug delivery systems for the treatment of retinal diseases.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.004
Targeting P2X7 receptors as a means for treating retinal disease.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.029
Multiscale modelling of drug mechanism and safety.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.12.009
Accelerated drug discovery by rapid candidate drug identification.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.026
Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.07.005
The Horizon Scanning System at The Italian Medicines Agency.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.010
Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.10.002
Physiologically based ocular pharmacokinetic modeling using computational methods.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.039
Collaborative drug discovery and the Tres Cantos Antimalarial Set (TCAMS).
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.005
Impact of dosing schedule in animal experiments on compound progression decisions.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.006
Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.10.001
Novel insights into the role of urotensin II in cardiovascular disease.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.08.005
Regulatory aspects and quality controls of polymer-based parenteral long-acting drug products: the challenge of approving copies.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.12.008
CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.07.002
Adverse drug reactions on sexual functioning: a systematic overview.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.01.012
Correlates of time to approval and other clinical development periods.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.027
Neuropharmacokinetics: a bridging tool between CNS drug development and therapeutic outcome.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.02.007
Drug discovery: a research sector stricken in France that can sometimes pay off.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.002
